FDA Drug Discontinuation

$179 / year

The Food and Drug Administration (FDA) Drug discontinuation database includes information about current drugs in discontinuations of specific drug products, resource information, and relevant links.

Complexity

The Food and Drug Administration (FDA) Drug discontinuation database includes information about current drugs in discontinuations of specific drug products including posting date, updated date, therapeutic category, resource information and relevant links.

Date Created

2014-01

Last Modified

2020-07-24

Version

2020-07-24

Update Frequency

Irregular

Temporal Coverage

N/A

Spatial Coverage

United States

Source

John Snow Labs; U.S. Food and Drug Administration (FDA);

Source License URL

Source License Requirements

N/A

Source Citation

N/A

Keywords

FDA Drug Discontinuation, Drug Discontinuation, FDA Drug Database, FDA Drugs, Current Drug Discontinuations, Drug Discontinuation

Other Titles

Discontinuations Reported to FDA, Discontinuations Listed by Generic Name or Active Ingredient

NameDescriptionTypeConstraints
Generic_Name_or_Active_IngredientProduct Namestringrequired : 1
Therapeutic_CategoriesTherapeutic Categories to productsstring-
LaboratoryLaboratory (MA Holder)stringrequired : 1
Last_UpdateLast status update datedate-
Laboratory_Contact_InformationCompany Contact Informationstring-
PresentationPresentation of products including NDCstring-
Date_First_PostedPosting Datedate-
Related_InformationRelated Information about shortagestring-
Date_DiscontinuedDiscontinue Datedate-
Generic Name or Active IngredientTherapeutic CategoriesLaboratoryLast UpdateLaboratory Contact InformationPresentationDate First PostedRelated InformationDate Discontinued
Abciximab (ReoPro) InjectionCardiovascularJanssen Biotech, Inc.2019-08-15800-586-77362mg/mL (NDC 57894-200-01)2018-04-11Janssen has made a business decision to discontinue manufacture of the drug product.2019-08-15
Abiraterone Acetate TabletsOncologyJanssen Research and Development, LLC2020-06-05800-526-7736250 mg tablets (NDC 57894-155-12)2020-06-052020-06-05
Acarbose (Precose) TabletsEndocrinology/MetabolismBayer2019-02-01888-842-2937Bottles of 100 Tablets 25 mg (NDC 50419-863-51)2019-02-01Business decision to discontinue marketing in the US.2019-02-01
Acarbose (Precose) TabletsEndocrinology/MetabolismBayer2019-02-01888-842-2937Bottles of 100 Tablets 50 mg (NDC 50419-861-51)2019-02-01Business decision to discontinue marketing in the US.2019-02-01
Acarbose (Precose) TabletsEndocrinology/MetabolismBayer2019-02-01888-842-2937Bottles of 100 Tablets 100 mg (NDC 50419-862-51)2019-02-01Business decision to discontinue marketing in the US.2019-02-01
Acarbose (Precose) TabletsEndocrinology/MetabolismBayer2019-02-01888-842-2937Unit Dose 50 mg (NDC 50419-861-48)2019-02-01Business decision to discontinue marketing in the US.2019-02-01
Acetaminophen/Tramadol Hydrochloride (Ultracet) TabletsAnalgesia/AddictionJanssen Pharmaceuticals2020-04-01800-526-7736325 mg/1 unit || 37.5 mg/1 unit (NDC 50458-650-60)2020-04-01The Company has made a business decision to permanently discontinue Ultracet. Product should be maintained on the formularies until the last batch produced expires (31 Oct 2022), in order to maintain continuity of the reimbursement process.2020-04-01
Acrivastine and Pseudoephedrine Hydrochloride CapsulesPulmonary/AllergyEndo Pharmaceuticals, Inc.2020-06-02800-462-3636Semprex-D Capsules, 8 mg/ 60mg , 100 capsules, (NDC 52244-404-10)2020-06-02Endo has made a business decision to permanently discontinue the drug product.2020-06-02
Acyclovir Capsules, USPAntiviralTeva Pharmaceuticals2019-03-21800-545-8800200 mg, 100 count (NDC 0093-8940-01)2019-03-21Teva made a business decision to discontinue product.2019-03-21
Acyclovir Capsules, USPAntiviralTeva Pharmaceuticals2019-03-21800-545-8800200 mg, 500 count (NDC 0093-8940-05)2019-03-21Teva made a business decision to discontinue product.2019-03-21